瘤内免疫注射药物及药物递送载体的研究进展  

Research progress of intratumoral immune injection of drugs and drug delivery carriers

作　　者：欧阳苏瑞 孙梦颖 唐桩 李进[1] 何敬东[1] Ouyang Surui;Sun Mengying;Tang Zhuang;Li Jin;He Jingdong(Department of Oncology,Affiliated Huaian No.1 Hospital of Nanjing Medical University,Huai'an 223300,China)

机构地区：[1]南京医科大学附属淮安第一医院肿瘤内科,淮安223300

出　　处：《国际肿瘤学杂志》2025年第3期169-175,共7页Journal of International Oncology

基　　金：淮安市级科技计划专项(HAB202018)。

摘　　要：近年来,瘤内免疫注射作为晚期恶性肿瘤治疗的一种新兴用药方式,通过将细菌和毒素、溶瘤病毒、细胞因子、单克隆抗体、免疫细胞、模式识别受体激动剂、化疗药物、mRNA、抗体偶联药物等注射入实体瘤内,不仅可提高药物的生物利用度,还可降低全身系统性毒性。此外,碘油、水凝胶、纳米颗粒、载药微球等药物递送载体的发展解决了瘤内注射的药物易经脉管系统扩散、难以在局部长期存留的问题。深入探讨瘤内免疫注射药物及药物递送载体的研究进展,可为瘤内免疫注射的进一步研究提供参考,提高实体瘤患者的临床获益。In recent years,intratumoral immune injection,as an emerging drug delivery modality in the treatment of advanced malignant tumors,has not only improved drug bioavailability,but also reduced systemic toxicity by injecting bacteria and toxins,oncolytic viruses,cytokines,monoclonal antibodies,immune cells,pattern recognition receptor agonists,chemotherapeutic agents,mRNA,and antibody-drug conjugates into solid tumors.In addition,the development of drug delivery carriers such as iodized oil,hydrogel,nanoparticles and drug-carrying microspheres has solved the problem that drugs injected intratumorally are prone to diffuse through the vascular system and are difficult to remain locally for a long period of time.An in-depth exploration of the research progress of intratumoral immune injection of drugs and drug delivery carriers can provide a reference for further research on intratumoral immune injection,and improve the clinical benefits for patients with solid tumors.

关 键 词：肿瘤 瘤内注射 药物递送载体 局部免疫治疗 

分 类 号：R730.5[医药卫生—肿瘤]